Skip to main content

FDA Approvals

FDA Approvals
FDA Approves Pombiliti Plus Opfolda for Treatment of Pompe Disease
Read More
FDA Approvals
Tofidence, First Biosimilar to Actemra, FDA Approved for Rheumatoid Arthritis and 2 Forms of Juvenile Idiopathic Arthritis
Read More
FDA Approvals
FDA Approved Rivfloza for Treatment of Primary Hyperoxaluria Type 1 in Children and Adults
Read More
FDA Approvals
Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation
Read More
FDA Approvals
Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma
Read More
FDA Approvals
Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer
Read More
FDA Approvals
IMJUDO (Tremelimumab-actl) in Combination With IMFINZI (Durvalumab) Receives FDA Approval for HCC and NSCLC
Jerm Day-Storms, PhD, MWC
Read More
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, October 4, 2022, Through August 4, 2023
Read More
FDA Approvals
FDA Approval of SYFOVRE (Pegcetacoplan) and IZERVAY (Avacincaptad Pegol) Reshapes Management of GA
Jerm Day-Storms, PhD, MWC
Read More
FDA Approvals
FDA Pipeline, October-December 2023
Read More
Page 4 of 53
Results 31 - 40 of 524